Physician profile
Liam Christopher Cunningham
NPI 1508472622
$1,812.89
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $408 · 2023: $62.47 · 2024: $35.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $389.82 | 2021 | |
| Boston Scientific Corporation | $196.67 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.50 | 2021 | |
| Collegium Pharmaceutical, INC. | $183.30 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $129.69 | 2021 | |
| Nevro Corp. | $125.42 | 2021 | |
| Abbvie INC. | $119.03 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $108.10 | 2021-2022 | |
| Almatica Pharma LLC | $61.88 | 2021-2022 | |
| Redhill Biopharma INC. | $54.56 | 2021 | |
| Lilly USA, LLC | $53.03 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $51.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.12 | 2022 | |
| Bioventus LLC | $32.65 | 2021 | |
| Uswm, LLC | $30.68 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $16.72 | 2022 | |
| Horizon Therapeutics Plc | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liam Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.